Rani Financial Statements From 2010 to 2026

RANI Stock  USD 1.39  0.01  0.72%   
Rani Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Rani Therapeutics' valuation are provided below:
Gross Profit
1.2 M
Market Capitalization
169.3 M
Enterprise Value Revenue
121.7328
Revenue
1.2 M
Earnings Share
(0.77)
We have found one hundred twenty available trending fundamental ratios for Rani Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Rani Therapeutics recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year.

Rani Therapeutics Total Revenue

691,466

Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.3 M, Depreciation And Amortization of 742.1 K or Interest Expense of 6.1 M, as well as many indicators such as Price To Sales Ratio of 41.46, Dividend Yield of 0.0 or PTB Ratio of 18.51. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Rani Stock
Check out the analysis of Rani Therapeutics Correlation against competitors.

Rani Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets57.2 M33 M42.7 M
Slightly volatile
Short and Long Term Debt Total33.5 M26.7 M78.8 M
Slightly volatile
Other Current Liabilities1.4 M1.9 M2.4 M
Slightly volatile
Total Current Liabilities24 M22.9 M7.2 M
Slightly volatile
Property Plant And Equipment Net6.3 M7.6 M5.2 M
Slightly volatile
Accounts Payable968.4 K1.6 M564.4 K
Slightly volatile
Cash3.2 M3.4 M23.5 M
Very volatile
Non Current Assets Total6.6 M7.9 M6.2 M
Slightly volatile
Non Currrent Assets Other210.3 K221.4 K1.2 M
Slightly volatile
Cash And Short Term Investments23.6 M24.9 M34.1 M
Slightly volatile
Net Receivables519.6 K385.2 K361.9 K
Pretty Stable
Common Stock Shares Outstanding24.7 M32.7 M21.2 M
Slightly volatile
Liabilities And Stockholders Equity57.2 M33 M42.7 M
Slightly volatile
Non Current Liabilities Total11.3 M11.9 M84.7 M
Slightly volatile
Inventory0.80.90.9824
Slightly volatile
Other Current Assets1.6 M1.9 M802.3 K
Slightly volatile
Other Stockholder Equity126.7 M120.6 M33.9 M
Slightly volatile
Total Liabilities55.3 M29.8 M92.7 M
Slightly volatile
Property Plant And Equipment Gross8.8 M13 M7.1 M
Slightly volatile
Total Current Assets52.4 M26.8 M36.7 M
Slightly volatile
Capital Stock4.3 K4.5 K431.3 K
Slightly volatile
Net Working Capital8.4 M8.9 M28.7 M
Slightly volatile
Common Stock4.3 K4.5 K431.3 K
Slightly volatile
Property Plant Equipment5.4 M6.9 M4.9 M
Slightly volatile
Long Term Debt18.1 M11.1 M8.7 M
Slightly volatile
Short and Long Term Debt18.1 M17.2 M4.7 M
Slightly volatile
Short Term Debt19.9 M18.9 M4.6 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity29.7 M33.4 M36.5 M
Slightly volatile
Common Stock Total EquityK4.5 K4.9 K
Slightly volatile
Long Term Debt Total23.3 M26.2 M28.6 M
Slightly volatile
Capital Surpluse60.7 M68.3 M74.5 M
Slightly volatile
Non Current Liabilities Other47.2 K53.1 K58 K
Slightly volatile

Rani Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.3 MM832.5 K
Slightly volatile
Depreciation And Amortization742.1 K1.2 M649.9 K
Slightly volatile
Interest Expense6.1 M5.8 M1.4 M
Slightly volatile
Selling General Administrative20.8 M27.5 M11.4 M
Slightly volatile
Other Operating Expenses51.9 M62.5 M38.2 M
Slightly volatile
Research Development30.4 M30.7 M26.4 M
Slightly volatile
Total Operating Expenses51.8 M62.5 M38.2 M
Slightly volatile
Reconciled Depreciation732.4 K1.2 M646.2 K
Slightly volatile
Cost Of Revenue853.6 K739.8 K1.2 M
Slightly volatile
Non Operating Income Net Other998.4 K1.1 M1.2 M
Slightly volatile
Selling And Marketing Expenses657.6 K739.8 K807.5 K
Slightly volatile

Rani Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.4 M5.7 M40.4 M
Pretty Stable
Depreciation742.1 K1.2 M649.9 K
Slightly volatile
Capital Expenditures229.1 K241.2 K1.2 M
Slightly volatile
Total Cash From Financing Activities11.6 M12.2 M13.2 M
Slightly volatile
End Period Cash Flow3.6 M3.8 M23.6 M
Very volatile
Other Cashflows From Investing Activities769.3 K1.4 M426.5 K
Slightly volatile
Dividends Paid23.7 M26.7 M29.1 M
Slightly volatile
Cash Flows Other Operating404 K454.5 K496.1 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio41.4643.64177
Slightly volatile
Days Sales Outstanding130137186
Pretty Stable
Stock Based Compensation To Revenue9.5714.0310.0104
Slightly volatile
Capex To Depreciation0.280.32.1399
Slightly volatile
EV To Sales69.0372.67233
Slightly volatile
Payables Turnover0.861.140.9541
Slightly volatile
Sales General And Administrative To Revenue22.0120.969.9547
Slightly volatile
Research And Ddevelopement To Revenue23.8929.8524.6167
Very volatile
Capex To Revenue0.280.31.1938
Slightly volatile
Cash Per Share1.061.121.6015
Slightly volatile
Days Payables Outstanding382331386
Slightly volatile
Income Quality0.690.721.1133
Very volatile
Current Ratio1.631.728.237
Pretty Stable
Receivables Turnover2.422.763.1892
Slightly volatile
Capex Per Share0.01030.01080.0608
Slightly volatile
Revenue Per Share0.04940.03250.0498
Very volatile
Interest Debt Per Share1.831.43.8757
Slightly volatile
Debt To Assets1.470.933.2064
Slightly volatile
Operating Cycle130137186
Pretty Stable
Days Of Payables Outstanding382331386
Slightly volatile
Ebt Per Ebit1.020.650.948
Slightly volatile
Quick Ratio1.631.728.237
Pretty Stable
Net Income Per E B T0.80.580.8556
Slightly volatile
Cash Ratio0.210.226.617
Very volatile
Days Of Sales Outstanding130137186
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.141.161.0626
Pretty Stable
Fixed Asset Turnover0.220.140.2185
Very volatile
Debt Ratio1.470.933.2064
Slightly volatile
Price Sales Ratio41.4643.64177
Slightly volatile
Asset Turnover0.02710.03230.0351
Slightly volatile

Rani Fundamental Market Drivers

Rani Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.3 M-1.2 M
Total Revenue925.2 K691.5 K
Cost Of Revenue739.8 K853.6 K
Stock Based Compensation To Revenue 14.03  9.57 
Sales General And Administrative To Revenue 20.96  22.01 
Research And Ddevelopement To Revenue 29.85  23.89 
Capex To Revenue 0.30  0.28 
Revenue Per Share 0.03  0.05 
Ebit Per Revenue(59.64)(62.62)

Currently Active Assets on Macroaxis

When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.77)
Revenue Per Share
0.032
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.96)
Return On Equity
(11.88)
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.